Longwood Fund
Overview
Longwood Fund is a venture capital firm dedicated to creating and investing in novel healthcare companies that develop important treatments to help patients while generating significant value for investors . The Longwood team has a long history of successfully launching and building important life science companies while providing operational leadership and strategic guidance . Collectively, the Partners at Longwood Fund have co-founded approximately 25 companies with over 20 launched or marketed drugs and therapies, as well as over two dozen clinical-stage assets, all focused on helping patients in need .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Khartis Therapeutics | Aug 2026 | Series B | Co-investor |
| Crystalys Therapeutics | Jul 2026 | Series B | Co-investor |
| Avenzo Therapeutics | Jun 2026 | Private Placement | Co-investor |
| Coultreon Biopharma | Apr 2026 | Series A | Co-investor |
| Neomorph | Apr 2026 | Series B | Co-investor |
Key People
John McCabe
Operating Partner
Rob Hadfield
General Counsel And Operating Partner
Annalisa D'Andrea
Venture Partner
Lea Hachigian
Venture Partner
Roger Tung
Venture Partner
Aleks Radovic-Moreno
Partner
David Donabedian
Executive Partner
Vikas Goyal
Partner, Growth Investments
Lucy Liu
Principal
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
